Naltrexone in Treatment of Cocaine Dependence - 5

National Institute on Drug Abuse (NIDA)

Overview

The purpose of this study is to determine the efficacy of naltrexone in the treatment of cocaine dependence as measured by: 1) decreased urine benzoylecgonine (BE) levels, 2) decreased cocaine use by self-report, 3) decreased cocaine craving, and 4) retention in treatment.

Double-blind, placebo controlled study of the safety and efficacy of naltrexone in treating cocaine dependence in a patient sample that initiated the study while in an inpatient setting and were then followed-up for 3 months as outpatients.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Cocaine-Related Disorders

Interventions

NaltrexoneDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Meet DSM-III-R criteria for cocaine dependency, 2. 18 to 65 years of age, 3. capable of understanding the study, 4. voluntarily signed consent, 5. male or non-pregnant female using approved form of birth control. Exclusion Criteria: 1. abnormal liver function tests (SGOT, SGPT, or GGT greater than twice the normal values), 2. opioid use within the last 7 days, 3. use of neuroleptics, 4. having a severe acute medical problem, 5. unable to complete psychiatric rating scales, or 6. judged by the investigator to be unlikely to comply with the study protocol

Locations (1)

Cincinnati MDRU

Cincinnati, Ohio, United States

Outcomes

Primary Outcomes

Retention

Cocaine use

Depression

Anxiety

Addiction severity

Global improvement

Psychopathology

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.